We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+23.32%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
-$11.8M
(-1%)
Cap. Flow
+$77.2M
Cap. Flow
% of AUM
6.76%
Top 10 Holdings %
Top 10 Hldgs %
64.3%
Holding
85
New
15
Increased
23
Reduced
19
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Natera
NTRA
|
+$51.9M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$37.6M |
| 3 |
Sanofi
SNY
|
+$26.7M |
| 4 |
Biogen
BIIB
|
+$21.8M |
| 5 |
GSK
GSK
|
+$18.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$96.3M |
| 2 |
Community Health Systems
CYH
|
+$21M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$17M |
| 4 |
Lantheus
LNTH
|
+$14.6M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
+$13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.7% |
| 2 | Miscellaneous | 9.48% |
| 3 | Communication Services | 0.77% |
| 4 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Milestone Pharmaceuticals
MIST
$144M
| – | – |
-126,826
| Closed | -$1.17M |
|
77
CALL
Maravai LifeSciences
MRVI
$1.14B
| – | – |
-24,000
| Closed | -$613K |
|
|
78
Maravai LifeSciences
MRVI
$1.14B
| – | – |
-160,000
| Closed | -$4.08M |
|
79
PUT
Invesco QQQ Trust
QQQ
$489B
| – | – |
-781,700
| Closed | -$209M |
|
|
THRD
80
DELISTED
Third Harmonic Bio
THRD
| – | – |
-10,000
| Closed | -$190K |
|
81
Viridian Therapeutics
VRDN
$2.61B
| – | – |
-478,387
| Closed | -$9.81M |
|
|
PNT
82
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| – | – |
-410,052
| Closed | -$3.17M |
|
|
ABMD
83
DELISTED
Abiomed Inc
ABMD
| – | – |
-52,970
| Closed | -$13M |
|
|
AERI
84
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-256,289
| Closed | -$3.88M |
|
|
BHVN
85
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-637,139
| Closed | -$96.3M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q4 2022 Portfolio in Review
As of Q4 2022, Eversept Partners held 85 positions worth $1.14B, down 1% from $1.15B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Eversept Partners deployed $77.2M of net new capital in Q4 2022, opening 15 new positions and adding to 23 existing holdings. Its largest new stake was CATALENT, INC.: 691,677 shares worth $31.1M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 72% a quarter earlier, followed by Miscellaneous and Communication Services.
On the sell side, the largest reduction was Community Health Systems, an estimated $21M trimmed.
- Eversept Partners's largest Q4 2022 buy was CATALENT, INC.: 691,677 shares worth $31.1M.
- Eversept Partners added most to Natera in Q4 2022, an estimated $51.9M increase.
- Eversept Partners's biggest Q4 2022 reduction was Community Health Systems, cutting an estimated $21M.
- Eversept Partners fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $96.3M.
- Eversept Partners's ten largest holdings make up 64% of its $1.14B portfolio in Q4 2022.
- Eversept Partners opened 15 new positions and closed 17 in Q4 2022.
- Eversept Partners's portfolio value fell 1% quarter-over-quarter to $1.14B.
Based on Eversept Partners's 13F filing for Q4 2022, filed 14 Feb 2023.